APA (7th ed.) Citation

SE, P., BL, K., GA, K., M, K., TL, T. H., WA, B., . . . CH, v. E. (2014). [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: An overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy. Cancer biotherapy & radiopharmaceuticals, 29(4), 179. https://doi.org/10.1089/cbr.2013.1552

Chicago Style (17th ed.) Citation

SE, Pool, Kam BL, Koning GA, Konijnenberg M, Ten Hagen TL, Breeman WA, Krenning EP, de Jong M, and van Eijck CH. "[(111)In-DTPA]octreotide Tumor Uptake in GEPNET Liver Metastases After Intra-arterial Administration: An Overview of Preclinical and Clinical Observations and Implications for Tumor Radiation Dose After Peptide Radionuclide Therapy." Cancer Biotherapy & Radiopharmaceuticals 29, no. 4 (2014): 179. https://doi.org/10.1089/cbr.2013.1552.

MLA (9th ed.) Citation

SE, Pool, et al. "[(111)In-DTPA]octreotide Tumor Uptake in GEPNET Liver Metastases After Intra-arterial Administration: An Overview of Preclinical and Clinical Observations and Implications for Tumor Radiation Dose After Peptide Radionuclide Therapy." Cancer Biotherapy & Radiopharmaceuticals, vol. 29, no. 4, 2014, p. 179, https://doi.org/10.1089/cbr.2013.1552.